SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11122207
This research explores new ways to treat acute myeloid leukemia (AML) by targeting specific proteins that help cancer cells survive.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11122207 on ClinicalTrials.gov |
What this research studies
Many patients with acute myeloid leukemia (AML) have mutations that lead to high relapse rates, and current treatments often face resistance. This project looks at how two proteins, SHP2 and BCL2, contribute to the survival of AML cells, especially those with specific mutations like FLT3 and KIT. Researchers are testing new SHP2 inhibitors in combination with an existing BCL2 inhibitor (venetoclax) to see if this combination can effectively stop cancer growth. They will also look for markers that predict who might respond best to this treatment and why some cells might become resistant. The aim is to find better treatment options for patients whose AML has relapsed or is resistant to current therapies.
Who could benefit from this research
Good fit: This research is relevant for patients with acute myeloid leukemia (AML), particularly those with FLT3 or KIT mutations, or those who have experienced relapse or resistance to current treatments.
Not a fit: Patients without acute myeloid leukemia or those whose disease does not involve the specific genetic mutations or resistance mechanisms targeted by this research may not directly benefit from this particular approach.
Why it matters
Potential benefit: If successful, this work could lead to new, more effective combination therapies for patients with acute myeloid leukemia, especially those who have relapsed or have specific genetic mutations.
How similar studies have performed: While FLT3 inhibitors and BCL2 inhibitors like venetoclax are clinically active, resistance remains a challenge, making the combination of SHP2 and BCL2 inhibition a novel approach to overcome this resistance.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SMITH, CATHERINE CHOY — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SMITH, CATHERINE CHOY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.